The first report of a multiclonal cluster of *Klebsiella pneumoniae* was published by Antoniadou *et al*[@ref1] in 2007 from a Greek intensive care unit (ICU). They reported 18 isolates of *K. pneumoniae* in 13 patients. There were six distinct clones identified by repetitive extragenic palindromic polymerase chain reaction (REP-PCR). A cluster of five cases of carbapenem-resistant colistin-resistant *K. pneumoniae* was identified at Detroit Medical Center[@ref2]. Genotyping in this cluster revealed two closely related clones which indicated a strong link for patient-to-patient transmission[@ref2]. Ghafur *et al*[@ref3] reported such pan drug-resistant (PDR) organisms in 13 patients from India. Colistin is an old antibiotic which has resurfaced in past few years due to rising incidence of multidrug resistance organisms[@ref3]. There have been reports of colistin-resistant and tigecycline-resistant *Acinetobacter baumanii* (resistant to both tigecycline and colistin) from north India[@ref4] which was 3.5 per cent of total and 16 per cent of all MDR organisms isolated from urine samples. Prior colistin exposure has been considered as an important association though not established in literature[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10].

We did a retrospective analysis of the case records of the patients who had any culture report positive for PDR organisms between May 1, 2016 and January 31, 2017 admitted in the three ICUs of Apollo Hospitals, Bhubaneswar, India. An organism was considered PDR if it was resistant to all antipseudomonal agents such as penicillins, cephalosporins, carbapenems, aminoglycosides, quinolones, monobactams and polymyxins. Cultures were done using VITEK-2 compact (Biomerieux India Pvt. Ltd, software version 8.01) for all specimens. The report of VITEK-2 and European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints (S≤2, R≥2)^3^ were followed for *Enterobacteriaceae, Pseudomonas* and *Acinetobacter* isolates which were considered resistant to colistin if the minimum inhibitory concentration (MIC) was ≥8 and 4 μg/ml, respectively, as per the Clinical and Laboratory Standards Institute (CLSI) guidelines[@ref3].

The reports of colistin resistance were confirmed by e-strip method \[Colistin Ezy MIC^™^ Strip (0.016-256 mcg/ml) from HiMedia Laboratories Pvt. Ltd., Mumbai\] in these isolates. Determination of an isolate as an infective pathogen or colonizer was done by two independent investigators who were blinded to the study design. The Acute Physiology Assessment and Chronic Health Evaluation (APACHE) II score on admission for all patients, their culture reports, antibiotics received and length of stay (LOS) in hospital along with outcome were analyzed.

There were a total of 1448 ICU admissions in three ICUs of the hospital during the study period. There were a total of 15 isolates of PDR organisms from 11 patients. There were six male and five female patients. Detailed information of these patients is summarized in the [Table](#T1){ref-type="table"}. Average length of hospital stay was 60.72 (range 25-123) days. The mean age of the patients was 61.8 (28-84) yr. *K. pneumoniae* was isolated from 10 cases, *Pseudomonas* from four (*P. aeruginosa* in 3 and *P. luteola* in 1 case) and *A. baumanii* from one case. These isolates were considered to be colonizer in five and infective pathogens in six patients. These PDR isolates were associated with catheter-associated urinary tract infection (7), tracheitis (4), bacteraemia (2), meningitis (1) and soft-tissue infection (1). Average APACHE II score was 24 (7-36) indicating sick patients with multiple co-morbidities and organ dysfunction. Nine patients had received prior (*i.e.*, before the development of PDR infections) colistin therapy due to the growth of multidrug-resistant bacteria isolates while two had no history of prior colistin treatment. Of the nine patients, eight had combined colistin therapy while one had colistin monotherapy.

###### 

Details of patients included in the study (n=11)

  Age (yr)   Gender   APACHE II score   Diagnosis                                   Sample                Pan drug resistant (PDR) organism   Prior colistin intake   Culture clearance   Infective pathogen/colonizer   LOS before PDR culture (days)   Treatment for PDR infection               Survival after PDR report   LOS (days)   General status around PDR report                Outcome
  ---------- -------- ----------------- ------------------------------------------- --------------------- ----------------------------------- ----------------------- ------------------- ------------------------------ ------------------------------- ----------------------------------------- --------------------------- ------------ ----------------------------------------------- ---------------------------------
  84         Male     36                Brain stem bleed with CKD                   Urine                 *Pseudomonas aeruginosa*            Yes                     Not cleared         Pathogen                       54                              Polymyxin with meropenem for 14 days      30                          84           GCS-5 Dialysis and ventilator dependent         Death
  62         Male     34                Urosepsis with acute kidney injury          Urine                 *P. aeruginosa*                     Yes                     Cleared             Pathogen                       15                              Polymyxin with imipenem for 10 days       19                          34           Improvement                                     Discharged
  72         Female   33                Meningitis, pneumonia and septic shock      Tracheal secretions   *Acinetobacter baumannii*           Yes                     Not repeated        Colonizer                      17                              Polymyxin with meropenem for eight days   8                           25           In septic shock and previous bed-bound status   Death
  28         Female   21                ARDS with critical illness polyneuropathy   Urine                 *Klebsiella pneumoniae*             Yes                                         Colonizer                      30                              Not treated                               Survived                    31           Improvement                                     Discharge
  63         Male     18                TBI, multiple contusion                     Urine                 *P. aeruginosa*                     Yes                     No growth           Pathogen                       25                              Polymyxin with meropenem for 14 days      30                          55           Moribund on dialysis                            Death
  77         Male     26                Severe TBI                                  Blood trachea         *K. pneumoniae*                     No                      MDR *Klebsiella*    Pathogen                       11                              Colistin with meropenem for 14 days       38                          49           Poor GCS (3), in shock                          Death
  46         Female   7                 Post-operative cranial tumour               CSF                   *K. pneumoniae*                     Yes                     Not cleared         Pathogen                       53                              Polymyxin with meropenem for 21 days      42                          95           Poor GCS (5), in shock and MODS                 Death
  51         Male     13                TBI                                         Urine                 *P. luteola*                        No                      Not done            Colonizer                      23                              Not treated                               9                           32           Improvement                                     Death due to pulmonary embolism
  56         Female   24                TBI                                         Urine trachea         *K. pneumoniae*                     Yes                     Not cleared         Colonizer                      38                              Polymyxin plus meropenem for 14 days      50                          88           Poor GCS                                        Death
  72         Female   23                Toxic epidermal necrosis and sepsis         Blood urine CVC tip   *K. pneumoniae*                     Yes                     Not cleared         Pathogen                       40                              Polymyxin B with meropenem for 14 days    10                          50           Poor status, Renal failure on dialysis          Death
  69         Male     26                Ischaemic stroke                            Trachea               *K. pneumoniae*                     Yes                     Cleared             Colonizer                      70                              Not treated                               53                          123          Poor                                            Death due to cardiac issues

TBI, traumatic brain injury; GCS, Glasgow coma scale; MODS, multiorgan dysfunction; CKD, chronic kidney disease; ARDS, acute respiratory distress syndrome; CVC, central venous catheter; CSF, cerebrospinal fluid; LOS, length of stay; PAN, pan drug resistant; MDR, multidrug resistant; APACHE, acute physiology and chronic health evaluation

Nine of these patients died while the two were discharged. The overall mortality (9/11, 81.81%) was due to the primary disease process and other co-morbid conditions. The high APACHE II scores of all the patients who died indicated the severity of the illness and co-morbid conditions. Two of the nine deaths were attributed to PDR infections (infection-related mortality 18.18%). One patient with traumatic brain injury (TBI) died due to pulmonary embolism after discharge from the hospital. Eight of the 11 patients had neurological issues (stroke and TBI) and had prolonged hospitalization. In two reports from a Greek ICU by Falagas *et al*[@ref5][@ref6], the overall death rate was 29 and 41.7 per cent, respectively. The infection-related mortality in the second series was 33.3 per cent[@ref6]. In the study reported by Tsioutis *et al*[@ref7], mortality was 23.8 per cent (5 of 21). In these studies, PDR infections were treated with colistin along with carbapenems and quinolones[@ref5][@ref6][@ref7]. Duration of treatment was between 8 and 34 days in these studies[@ref5][@ref6]. Except one, all our PDR-infected patients were treated with polymyxin along with third-generation cephalosporins or carbapenems for 14-20 days. Polymyxin was preferred over colistin due to its presumed lower nephrotoxicity[@ref11] as most patients had deranged renal parameters. In the previous studies, the patients were treated with colistin even though the isolates had *in vitro* resistance to the same drug[@ref5][@ref6][@ref7]. Tsioutis *et al*[@ref7] implicated a better cure rate with tigecycline in PDR cases than colistin. None of our patients were given tigecycline.

Multidrug-resistant organisms were present in nine of 11 patients before the development of PDR organisms. Three out of four colonizers were treated with colistin. The duration of colistin therapy was between 10 and 14 days. The growth of PDR organisms in two patients, who did not have any prior exposure to colistin, was thought to be transferred from other infected patients. The genetic analysis could not be done which was a limitation of our study. Increased exposure to colistin has been viewed as the single most important risk factor for the development of colistin resistance among Gram-negative bacteria in the previous studies[@ref1][@ref8][@ref9][@ref10][@ref12].

The average length of stay (LOS) was around 60 days which matched with other studies[@ref8][@ref10][@ref11][@ref12]. In such critical cases, the average LOS before PDR culture report was 34.18 days (11-70 days). The time gap between the identification of PDR infection and death in the nine patients varied between 8 and 53 days. All patients with PDR infections had long LOS with high APACHE II scores.

It is important that culture reports should be judiciously interpreted to differentiate between colonizer and infective pathogen before the treatment. Widespread indiscriminate use of colistin to treat carbapenem resistant Enterobacteriacae (CRE) and other Gram-negative organisms can lead to the emergence of PDR organisms. Strict implementation of antibiotic stewardship programme is essential to limit use and prevent abuse of colistin. A large prospective study is required to delineate the risk factors for such PDR infections in Indian hospitals.
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